Clinical trials
Recruiting Multiple Myeloma trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
152 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2016 | 1 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 14 |
| 2023 | 26 |
| 2024 | 31 |
| 2025 | 38 |
| 2026 | 29 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 152 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 14 |
| Janssen Research & Development, LLC | 5 |
| Peking University First Hospital | 5 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 5 |
| Chongqing Precision Biotech Co., Ltd | 4 |
| The First Affiliated Hospital of Soochow University | 4 |
| Zhejiang University | 4 |
| Zhujiang Hospital | 4 |
| Nanjing IASO Biotechnology Co., Ltd. | 3 |
| Pfizer | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 152 |
| Recurrence | 27 |
| Lymphoma | 11 |
| Leukemia, Plasma Cell | 10 |
| Leukemia, Myeloid, Acute | 7 |
| Neoplasms, Plasma Cell | 7 |
| Hematologic Neoplasms | 5 |
| Lymphoma, B-Cell | 5 |
| Lymphoma, Non-Hodgkin | 5 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 |
Trials
Showing 1 to 25 of 152. Each trial links to its page on Pharma Observatory.
52 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.